IP Library Granted Patent US 7,754,897
Granted Patent B2
US 7,754,897 · App. 11/455,280 · Granted Jul 13, 2010

Synthetic processes for the preparation of aminocyclohexyl ether compounds

Assignee: Cardiome Pharma Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,754,897
App. No.
11/455,280
Granted
Jul 13, 2010
Kind
B2
Abstract

This invention is directed to stereoselective synthesis of compounds of formula (I) or formula (II): or a pharmaceutically acceptable salt, ester, amide, complex, chelate, clathrate, solvate, polymorph, stereoisomer, metabolite or prodrug thereof; wherein R 3 , R 4 and R 5 are defined herein. Compounds of formula (I) and formula (II) are known to be useful in treating arrhythmias.

Claims (27)

1. A method of making a compound of formula (I):

or a pharmaceutically acceptable salt, ester, amide, clathrate with a cyclodextrin or solvate in a solution phase thereof as a single stereoisomer or as a mixture thereof;

wherein:

R 3 , R 4 and R 5 are independently bromine, chlorine, fluorine, carboxy, hydrogen, hydroxy, hydroxymethyl, methanesulfonamido, nitro, cyano, sulfamyl, trifluoromethyl, —CHF 2 , —SO 2 N(R 8 )R 9 , —OCF 3 , C 2 -C 7 alkanoyloxy, C 1 - C 6 alkyl, C 1 -C 6 alkoxy, C 7 -C 12 aralkoxy, C 2 -C 7 alkoxycarbonyl, C 1 -C 6 thioalkyl, aryl or —N(R 6 )R 7 ; and

R 6 , R 7 , R 8 , and R 9 are independently selected from hydrogen, acetyl, methanesulfonyl or C 1 -C 6 alkyl;

which method comprises:

a) reacting a compound of formula (4):

wherein each R 2a is O or H 2 where at least one R 2a in the compound of formula (4) is O, and R is H, C 2 -C 5 acyl or an oxygen-protecting group, with a compound of formula (5):

wherein R 3 , R 4 and R 5 are as defined above and Q is a leaving group, to form a compound of formula (6):

wherein each R 2a is O or H 2 where at least one R 2a is O, R is H, C 2 -C 5 acyl or an oxygen-protecting group and R 3 , R 4 and R 5 are as defined above, under suitable conditions such that upon reaction of the compound of formula (4) with the compound of formula (5), the trans relative configuration of the hydroxyl group on the carbon at the 1-position of the compound of formula (4) is retained in the carbon at the 1-position of the compound of formula (6);

b) reducing the compound of formula (6) under suitable conditions to form a compound of formula (I).

2. The method of claim 1 further comprising a deprotection step prior to the reaction of a compound of formula (4) with a compound of formula (5), wherein the deprotection step comprises treating a compound of formula (3):

wherein each R 2a is O or H 2 where at least one R 2a is O, R 1 is an oxygen-protecting group and R is H, C 2 —C 5 acyl or an oxygen-protecting group, to suitable deprotecting conditions to form a compound of formula (4) as set forth above.

3. The method of claim 2 wherein R 1 is an optionally substituted benzyl group and R is C 2 -C 5 acyl.

4. The method of claim 2 further comprising a cyclization step to form a compound of formula (3), wherein the cyclization step comprises reacting a compound of formula (7) or a compound of formula (8) or a mixture of a compound of formula (7) and a compound of formula (8):

wherein each R 1 is independently an oxygen-protecting group, each R 2a is O or H 2 , and R is H, C 2 -C 5 acyl or an oxygen-protecting group, under suitable conditions to form a compound of formula (3) as set forth above.

5. The method of claim 4 wherein R 1 is an optionally substituted benzyl group and R is C 2 -C 5 acyl.

6. The method of claim 4 further comprising a condensation step to form a compound of formula (7) or a compound of formula (8) or a mixture of a compound of formula (7) and a compound of formula (8), wherein the condensation step comprises reacting a compound of formula (1):

where R 1 is an oxygen-protecting group, with a compound of formula (2a):

wherein each R 2a is O or H 2 where at least one R 2a in the compound of formula (2a) is O, R is H, C 2 -C 5 acyl or an oxygen-protecting group, under suitable conditions to form the compound of formula (7) or the compound of formula (8) or the mixture of a compound of formula (7) and a compound of formula (8) as set forth above.

7. The method of claim 6 wherein R 1 is an optionally substituted benzyl group and R is C 2 -C 5 acyl.

8. The method of claim 1 further comprising the formation of an acid addition salt of the compound of formula (I).

9. The method of claim 1 wherein the compound of formula (I) is a compound of formula (I) where R 3 , R 4 and R 5 are independently hydrogen, hydroxy or C 1 -C 6 alkoxy; with the proviso that R 3 , R 4 and R 5 cannot all be hydrogen at the same time.

10. The method of claim 9 wherein the compound of formula (I) is a compound of formula (Ia):

or a pharmaceutically acceptable salt, ester, amide, clathrate with a cyclodextrin or solvate in a solution phase thereof.

11. The method of claim 9 wherein the compound of formula (I) is selected from the group consisting of:

or pharmaceutically acceptable salts, esters, amides, clathrates with a cyclodextrin or solvates in a solution phase thereof.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2018
From: CARDIOME PHARMA CORP.
To: CORREVIO CANADA CORP.
Reel/Frame 046831/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2018
From: CORREVIO CANADA CORP.
To: CORREVIO INTERNATIONAL SÀRL
Reel/Frame 046831/0227 →
RELEASE OF SECURITY INTEREST Recorded Jun 20, 2016
From: MIDCAP FINANCIAL TRUST
To: CARDIOME PHARMA CORP.; CARDIOME, INC.; ARTESIAN THERAPEUTICS, INC.; MURK ACQUISITION SUB, INC.; CORREVIO LLC; CARDIOME INTERNATIONAL AG; CORREVIO INTERNATIONAL SARL; CORREVIO (UK) LTD.; CARDIOME UK LIMITED; CORREVIO (AUSTRALIA) PTY LTD.
Reel/Frame 038961/0202 →
SECURITY INTEREST Recorded Jul 24, 2014
From: CARDIOME PHARMA CORP.; CARDIOME, INC.; ARTESIAN THERAPEUTICS, INC.; MURK ACQUISITION SUB, INC.; CORREVIO LLC; CARDIOME INTERNATIONAL AG; CORREVIO INTERNATIONAL SARL; CORREVIO (UK) LTD.; CARDIOME UK LIMITED; CORREVIO (AUSTRALIA) PTY LTD.
To: MIDCAP FUNDING V, LLC
Reel/Frame 033407/0314 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2006
From: JUNG, GRACE; YEE, JAMES GEE KEN; CHOU, DOUG TA HUNG; PLOUVIER, BERTRAND M. C.
To: CARDIOME PHARMA CORP.
Reel/Frame 018229/0544 →
Continuity (3)
Provisional Application 6074824800 · Dec 7, 2005
Provisional Application 6069098900 · Jun 15, 2005
Related Publication 20070015924A1 · Jan 18, 2007